Introduction:The excretory insufficiency of pancreas in patients with primary osteoarthrosis is formed at the comorbid pathologies and as a result of long-term treatment of osteoarthrosis using the non-steroidal anti-inflammatory drugs, steroids, chondroprotectors and chondrostimulators etc. The aim: to study the state of the proteolysis system and immune status, the presence and depth of the dysbiosis of colon in patients with primary osteoarthrosis against a violation of their excretory insufficiency of pancreas.
Materials and methods: There were 64 outpatients with primary OA (group 1) and 74 patients with primary OA in combination with diseases associated with EIP (group 2). The control group consisted of 30 healthy people.The age of the patients ranged from 29 to 74 years. The diagnosis of primary OA was established on the basis of unified diagnostic criteria, the X-ray stage of the primary OA, according to J. H. Kellgren and J. S. Lawrence.
Results: It was proved that there is a deeper excitation of the excretory function of the pancreas in patient with osteoarthrosis and comorbid pathologies of the gastrointestinal tract with the excretory insufficiency of pancreas, as well as the presence of the excretory insufficiency of pancreas in patients with primary osteoarthrosis without the clinically available the excretory insufficiency of pancreas. In patients with primary osteoarthrosis that went through the isolation or in combination with the diseases accompanied by theexcretory insufficiency of pancreas, a statistically significant activation of the total proteolysis by the level of the proteolytic activity of the plasma was established. In group 2, dysbiotic changes were significantly deeper than in group 1. The obtained results indicate the presence of secondary immune deficiency in patients and non-specific activation of the humoral part of the immune system and the inflammatory process.
Conclusion: Statistically more significant changes were observed in group 2, indicating the progression of the detected changes in comorbidity conditions.